Australian Pharma Stock News

CSL (ASX:CSL) is back in focus after the European Medicines Agency’s committee recommended revoking the EU marketing authorisation for Tavneos. This has raised fresh questions about the CSL Vifor unit and the stock’s recent recovery. See our latest analysis for CSL. The Tavneos setback arrives after a sharp 27.21% 1 month share price return for CSL. However, this sits against a weaker backdrop, with the stock down 31.52% year to date and the 1 year total shareholder return declining 49.94%,...

Silex Systems (ASX:SLX) is back in focus after completing and beginning commissioning of its laser based Quantum Silicon production plant in Sydney, while interest builds around its nuclear fuel and quantum computing technology platform. See our latest analysis for Silex Systems. Silex Systems' recent commissioning update comes as the stock trades at A$5.71, with a 1 day share price return of 7.74%, a 90 day share price return of 10.44%, and a 5 year total shareholder return that is very...

Neuren Pharmaceuticals (ASX:NEU) is back in focus after the European Medicines Agency's CHMP issued a positive opinion on its Rett syndrome treatment Daybue, clearing the path toward potential approval and European launch. See our latest analysis for Neuren Pharmaceuticals. That CHMP opinion has coincided with a sharp shift in sentiment toward Neuren Pharmaceuticals. The 7 day share price return of 36.82% and 90 day share price return of 46.72% contrast with a year to date share price decline...

Analyst estimates suggest these rare earth stocks may deliver a significant earnings uplift over the next several years.

Elsight Ltd (ASX:ELS), which provides secure connectivity technology for drones and autonomous systems, has recently attracted renewed investor interest as defence and unmanned-sector narratives strengthen globally and its multi-channel communication solutions address critical beyond-visual-line-of-sight data transmission needs across defence, logistics, agriculture, and public safety. An interesting angle is how rising global defence budgets and expanding regulatory acceptance of long-range...

Why this FDA milestone matters for Mesoblast Mesoblast (ASX:MSB) stock is in focus after the US FDA assigned a Biologics License Application filing number for rexlemestrocel-L and accepted a modular review request for patients with LVAD-related risks. This regulatory step, supported by existing Orphan Drug and Regenerative Medicine Advanced Therapy designations, provides formal structure around the approval process for Mesoblast’s late-stage heart failure program and clarifies the path for...

Ramsay Health Care has recently progressed its proposed demerger of European subsidiary Ramsay Santé, alongside reporting stabilising FY25 financial performance despite sector-wide cost pressures. This combination of portfolio simplification and steadier earnings has put Ramsay back in focus as investors reassess the healthcare sector’s fundamentals. We’ll now explore how the Ramsay Santé demerger proposal could reshape Ramsay Health Care’s existing investment narrative and longer-term...

Magellan Financial Group (ASX:MFG) has undergone a sweeping leadership reset, appointing Brian Benari as CEO, Gavin Buchanan as CFO, and reshaping its board with David Gonski AC as chairman and Andrew Formica as deputy chairman. See our latest analysis for Magellan Financial Group. The leadership overhaul has arrived alongside a sharp shift in sentiment around Magellan Financial Group, with the stock showing a 26.60% 30 day share price return and a 28.04% 1 year total shareholder return,...

As the Australian market opens the new financial year with little movement, hovering around 8,780 points, global influences like the U.S.-Iran tensions and tech-driven Wall Street gains continue to shape investor sentiment. Amidst these broader market dynamics, penny stocks remain a compelling area for those seeking investment opportunities in smaller or newer companies. Despite their somewhat outdated name, penny stocks can offer surprising value when backed by solid financials and...

Centuria Capital Group recently completed a A$200,000,000 follow-on equity offering at A$2.00 per stapled security as part of a fully underwritten A$300,000,000 equity raising, alongside confirming a final distribution of A$0.052 per stapled security for the six months to 30 June 2026. The capital raising supports Centuria’s A$454,000,000 acquisition of a 50% interest in Sydney CBD office assets via a new unlisted fund, signalling a meaningful expansion of its Australian office footprint and...

HUB24 Limited has appointed Mr. Andrew Formica as a Non-Executive Director, effective 1 July 2026, adding his 30-plus years of global investment management experience and placing him on the People and Culture, Audit and Nomination Committees. Formica’s concurrent roles at Magellan Financial Group, Barrenjoey and Vinva Holdings mean HUB24’s board now includes a director deeply engaged across multiple parts of the funds management and capital markets ecosystem. We’ll now examine how bringing...

Insiders who bought Way 2 Vat Ltd ( ASX:W2V ) stock in the last 12 months were richly rewarded last week. The company's...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Even if it's not a huge purchase, we think it was good to see that David Pevcic, the Executive Chairman of Nanoveu...

Gold has been back in the spotlight as investors and central banks look for shelter from geopolitical tensions, stubborn inflation pressures, and questions around government debt. For many, the Elite Gold Stocks screener is an efficient way to filter this noisy backdrop down to a focused list of gold mining companies with stronger balance sheets and lower production costs. That combination can help these miners stay more resilient if gold prices move around. In this article, you will see 3 of...

Orica has approved the development of a commercial-scale green hydrogen production facility in the Hunter Valley, targeted to begin operations in early 2029 and displacing part of its natural gas feedstock. The project is expected to cut the company’s carbon dioxide equivalent emissions by about 35,000 tonnes a year, underscoring how emissions reduction is becoming central to Orica’s long-term industrial footprint. We’ll now examine how Orica’s decision to invest in a commercial-scale green...

Even if it's not a huge purchase, we think it was good to see that Russel Pillemer, the CEO & Executive Director of...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

As the Australian share market opens the new financial year with little movement, hovering around 8,780 points, investors remain cautious amid global uncertainties such as geopolitical tensions and fluctuating commodity prices. In this environment, growth companies with strong insider ownership can offer a unique appeal, as they often signal confidence from those who know the business best and may provide resilience in uncertain times.

As the Australian market opens the new financial year with a steady performance, hovering around 8,780 points in futures, investors are closely watching global influences such as U.S.-Iran tensions and Wall Street's tech-driven momentum. In this environment of cautious optimism and fluctuating commodity prices, identifying undervalued stocks like FINEOS Corporation Holdings can offer potential opportunities for those seeking value investments amidst broader economic uncertainties.

As the Australian market opens the new financial year with a steady outlook, global indices such as the Nasdaq and FTSE are showing positive momentum, reflecting broader market sentiment influenced by factors like U.S. consumer confidence and geopolitical tensions. In this environment, identifying promising small-cap stocks can be key to enhancing your portfolio, especially when these companies demonstrate resilience and potential for growth amidst fluctuating economic conditions.

As the Australian market starts the new financial year on a flat note, with the ASX hovering around 8,780 points, global influences such as U.S.-Iran tensions and tech-driven gains in Wall Street continue to shape investor sentiment. Penny stocks, although an older term, remain relevant for those looking at smaller or newer companies that often offer potential growth at lower price points. By focusing on those with strong balance sheets and solid fundamentals, investors can uncover hidden...

In late June 2026, Judo Capital Holdings cut its FY26 profit-before-tax target to A$163 million–A$169 million and disclosed three rapidly deteriorating SME loan exposures totaling about A$70 million–A$80 million, representing roughly 0.5% of its loan book. This combination of lowered profit ambitions and emerging credit issues has sharpened investor focus on Judo’s risk controls and the resilience of its relationship-led SME lending model. We’ll now consider how this profit downgrade and...